1-2 of 2
Veronica Bunn
Close
Sort by
Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, Owen A. O'Connor, MD, Barbara Pro, MD, Tim Illidge, MD PhD, Swami P. Iyer, MD, Ranjana Advani, MD, Nancy L. Bartlett, MD, Jacob Haaber Christensen, Franck Morschhauser, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, MD, Won Seog Kim, PhD, Tatyana A. Feldman, MD, Tobias Menne, MD PhD, David Belada, MD PhD, Árpád Illés, MD PhD, Kensei Tobinai, MD, Kunihiro Tsukasaki, MD PhD, Su-Peng Yeh, MD, Andrei R Shustov, MD, Andreas Hüttmann, MD, Kerry J. Savage, BSc, MD MSc, Sam Yuen, MBBS, FRACP, FRCPA, Pier Luigi Zinzani, MD, Harry Miao, MD, Veronica Bunn, PhD, Keenan Fenton, MA, Michelle A. Fanale, MD, Markus Puhlmann, MD, Lorenz Truemper, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-134398
Published: 2020
Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Kerry J Savage, BSc, MD MSc, Steven M. Horwitz, MD, Ranjana H Advani, MD, Jacob H. Christensen, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, Franck Morschhauser, MD, Onder Alpdogan, MD, Cheolwon Suh, Kensei Tobinai, MD PhD, Andrei R Shustov, MD, Marek Trneny, MD prof, Sam Yuen, MBBS,FRCPA,FRACP, Pier Luigi Zinzani, MD PhD, Lorenz Truemper, MD, Timothy Illidge, MD PhD, Owen O'Connor, MD PhD, Barbara Pro, MD, Meredith Little, MPH, Veronica Bunn, Keenan Fenton, Thomas Manley, MD, Swaminathan P. Iyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 464.
https://doi.org/10.1182/blood-2019-122781
Published: 2019